Tecos study pptx

FDA-Mandated CV Safety Trials - outpatient.aace.com

★ ★ ☆ ☆ ☆

FDA-Mandated CV Safety Trials. TECOS(Trial Evaluating Cardiovascular Outcomes with Sitagliptin) Clinical Outcomes with Antihyperglycemic Agents. Clinical Outcomes with Sitagliptin. Study Design. N=14,671 patients with T2D and CVD. Randomization. Sitagliptin: n=7332 (6972 completed)

FDA-Mandated CV Safety Trials - outpatient.aace.com

PowerPoint Presentation

★ ★ ★ ★ ★

TECOS(Trial Evaluating Cardiovascular Outcomes with Sitagliptin) Clinical Outcomes with Antihyperglycemic Agents. Clinical Outcomes with Sitagliptin. Study Design. ... Noninferiority study: prespecified margin = 1.3 for upper bound of 95% CI of the HR for the primary endpoint.

PowerPoint Presentation

Objectives and End Points of EXAMINE - Clinical Trial Results

★ ★ ★ ★ ★

Objectives and End Points of EXAMINE • Primary objective: To demonstrate that major CV event rates are not higher with alogliptin than with placebo in type 2 diabetes patients with recent ACS who are receiving standard of care for diabetes and secondary CV prevention – Primary end point: composite of first occurrence of CV death,

Objectives and End Points of EXAMINE - Clinical Trial Results

Cardiovascular Outcomes Trials in Diabetes

★ ★ ☆ ☆ ☆

Cardiovascular Outcomes Trials in Diabetes M. Angelyn Bethel, MD Deputy Director. University of Oxford Diabetes Trials Unit. ... Common outcomes are easy to study (cardiovascular ... TECOS. SAVOR. CAROLINA >35,000.

Cardiovascular Outcomes Trials in Diabetes

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

★ ★ ☆ ☆ ☆

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

Canagliflozin and Cardiovascular and Renal Events in Type ...

★ ★ ★ ★ ★

Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of ...

Canagliflozin and Cardiovascular and Renal Events in Type ...

The Diabetes Download: Diabetes Update - nmpharmacy.org

★ ★ ☆ ☆ ☆

(tecos) Toh S, Hamp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med

The Diabetes Download: Diabetes Update - nmpharmacy.org

PowerPoint Presentation

★ ★ ☆ ☆ ☆

TECOS (sitagliptin) and CARMELINA(linagliptin – results expected in 2018) trials are ongoing. (TECOS results are being expected this year), they will show if these drugs show CV safety and/or CV benefit, and it may confirm whether HF hospitalization seen with sitagliptin is a chance finding or class effect.

PowerPoint Presentation

Diabetes Treatments to Reduce CV Events in T2DM

★ ★ ☆ ☆ ☆

December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

Diabetes Treatments to Reduce CV Events in T2DM

3. TECOS Penelitian Pada k | Cardiovascular Diseases ...

★ ★ ★ ★ ☆

3. TECOS Penelitian Pada k - Download as Powerpoint Presentation (.ppt / .pptx), PDF File (.pdf), Text File (.txt) or view presentation slides online. tecos tecos

3. TECOS Penelitian Pada k | Cardiovascular Diseases ...

Clinical Application of New CV Outcomes Data

★ ★ ★ ★ ★

TECOS: Primary Composite CV OutcomeIntent-to-Treat Analysis for Superiority . ... Lixisenatide* ELIXAStudy Design. ELIXANo CV Risks of Benefits. Ongoing GLP-1 Receptor Agonist CV Outcomes Studies. SGLT2 InhibitorsMechanism of Action. EMPA-REG OUTCOME ... Clinical Application of New CV Outcomes Data Last modified by:

Clinical Application of New CV Outcomes Data

Dpp4 Inhibitors PPT | Xpowerpoint

★ ★ ★ ★ ☆

View and Download PowerPoint Presentations on Dpp4 Inhibitors PPT. Find PowerPoint Presentations and Slides using the power of XPowerPoint.com, find free …

Dpp4 Inhibitors PPT | Xpowerpoint

1-Gavin-The Heart of the Matter.pptx [Read-Only]

★ ★ ★ ★ ★

Study SAVOR EXAMINE TECOS CAROLINA CARMELINA DPP4-i saxagliptin alogliptin sitagliptin linagliptin linagliptin Comparator placebo placebo plcebo sulfonylurea placebo N 16,500 5,400 14,000 6,000 8,300 Results 2013 2013 June 2015 2017 2017 Study EMPA-REG CANVAS DECLARE NCT01986881 SGLT-2-i empaglifozin canagliflozin dapagliflozin ertugliflozin

1-Gavin-The Heart of the Matter.pptx [Read-Only]

CANVAS - CANagliflozin cardioVascular Assessment Study ...

★ ★ ☆ ☆ ☆

12/15/2009 · The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of ...

CANVAS - CANagliflozin cardioVascular Assessment Study ...

Peachtree Securities, Inc (B-2) | Preferred Stock | Cost ...

★ ★ ★ ★ ☆

Bond and Stock Valuation. Peachtree Securities, Inc. (B-2) What we need to know Common Stock A security that represents ownership in a corporation. Holders exercise control by electing a board of directors Common stockholders are on the bottom of the priority ladder for ownership structure. Preferred Stock A class of ownership in a corporation that has a higher claim on its assets and earnings ...

Peachtree Securities, Inc (B-2) | Preferred Stock | Cost ...

Empa Reg PPT | Xpowerpoint

★ ★ ★ ☆ ☆

View and Download PowerPoint Presentations on Empa Reg PPT. Find PowerPoint Presentations and Slides using the power of XPowerPoint.com, find free presentations research about Empa Reg PPT

Empa Reg PPT | Xpowerpoint

Tesco - SlideShare

★ ★ ☆ ☆ ☆

5/10/2012 · Tesco 1. byAshutosh Singh 2. ABOUT Tesco is a global grocery and general merchandise retailer headquartered in Cheshunt, United Kingdom. It is the third-largest retailer in the world measured by revenues (after Wal-Mart and Carrefour) and the second-largest measured by profits Tesco House, head office in Cheshunt, Hertfordshire. (after Wal-Mart). It has stores in 14 countries across Asia ...

Tesco - SlideShare

Introduction - Clinical Trial Results

★ ★ ★ ☆ ☆

All patients (including those who discontinued study drug or initiated new therapies) were included in this mixed model repeated measures analysis (intent-to-treat) X-axis: timepoints with reasonable amount of data available for pre-scheduled measurements Week Placebo 0 12 28 40 52 66 80 94 108 122 136 150 164 178 192 206 8.08 7 ...

Introduction - Clinical Trial Results

Case Study | Caesarean Section | Pain

★ ★ ☆ ☆ ☆

Case Study - Free download as Powerpoint Presentation (.ppt / .pptx), PDF File (.pdf), Text File (.txt) or view presentation slides online. Childbearing Case Study

Case Study | Caesarean Section | Pain

Cardiovascular Outcomes Trials Among DPP-4 Inhibitors

★ ★ ★ ★ ★

*TECOS is a randomised, double-blind, controlled CV safety trial, comparing sitagliptin and placebo when added to usual care in 14,671 patients with Type 2 diabetes and established CVD. Median follow up was 3.0 years; primary composite endpoint was CV death, nonfatal MI, nonfatal stroke or …

Cardiovascular Outcomes Trials Among DPP-4 Inhibitors

RedgedapS: Actualización de la Guía de Práctica Clínica ...

★ ★ ☆ ☆ ☆

Actualización de la Guía de Práctica Clínica “Diabetes Canada” Cada 5 años la Guía de Práctica Clínica (GPC) de la Canadian Diabetes Association actualiza su GPC con la introducción de la evidencia publicada hasta el momento.Esta es la sexta entrega desde su creación en 1992, pero en este momento con un cambio en el nombre, pasa de ser la GPC de la Canadian Diabetes Association a ...

RedgedapS: Actualización de la Guía de Práctica Clínica ...
Banqueting-kjv-bible-study.html,Bar-exam-study-meme.html,Barakova-study-prodej-domu.html,Barcelona-study-abroad-apartments.html,Bardin-monnier-study.html